Portfolio Lab

Repligen Corp

  • Stock
  • Ticker RGEN
  • ISIN US7599161095
  • Nasdaq

Health care · Biotechnology · USA

$163.81 −3.81%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Repligen Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

RGENGlobal equities (VT)

$10,000 grew to $50,403. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −68.3% in 05/2026, measured from the peak in 09/2021. The old peak has not been reached again yet.

1-year return
+6.1%
5-year return p.a.
−10.5%
10-year return p.a.
+17.6%
Volatility p.a.
38.9%
Largest decline
−68.3%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue168169182189198194204209
Gross profit399193101101108110111
Operating income-376.61417181614-30
EBITDA-18253437383633-10
Net income-345.81515138.35.0-38
Earnings per share-0.610.100.260.260.230.150.09-0.68
Balance sheet
Total assets2,8302,8522,9022,9242,9502,9312,9502,926
Liabilities857867840841844825838835
Equity1,9731,9852,0622,0832,1062,1052,1122,092
Cash757697709749566583607727
Long-term debt526––538542547551556
Cash flow
Operating cash flow3915294826283343
Capital expenditure-5.5-3.6-7.1-4.7-8.2-4.7-5.3-4.9
Free cash flow3411224318242738

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +107.2%, weakest 2022 at −36.1%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
30 Oct 2026−$0.68
29 Jul 2026$0.09
6 May 2026$0.15
26 Feb 2026$0.23
4 Nov 2025$0.26
7 Aug 2025$0.26
29 Apr 2025$0.10
14 Mar 2025−$0.61
18 Nov 2024−$0.01
30 Jul 2024$0.10
1 May 2024$0.06
22 Feb 2024−$0.28

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€9.5bn
Market cap in trading currency
$10.5bn
Enterprise value
$10.2bn
P/E
–
P/S
13.00
P/B
5.01
EV/Sales
12.62
EV/EBITDA
105.7
Earnings yield
–
FCF yield
1.0%

Results (last four quarters)

Revenue
$806m
Gross profit
$431m
EBITDA
$96.1m
Net income
−$11.8m
Earnings per share
−$0.21
Revenue per share
$12.60
Revenue growth
+10.9%
Earnings growth
−357.7%

Profitability

Gross margin
53.5%
Operating margin
2.3%
Net margin
-1.5%
Return on equity
-0.6%
Return on assets
-0.4%

Balance sheet and cash flow

Cash
$863m
Cash per share
$13.50
Financial debt
$556m
Debt/equity %
27
Current ratio
9.88
Book value per share
$32.72
Operating cash flow
$130m
Free cash flow
$107m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
63.9m
Volume
697,473
Avg. volume 3 months
1.20m
Relative volume
0.6

Price and technicals

Price
$163.81
1 day
−3.8%
52-week high
$194.57
52-week low
$102.87
Distance to 52-week high
−15.8%
Distance to 52-week low
+59.2%
Distance to 50-day line
−7.5%
Distance to 200-day line
+12.4%
RSI (14)
43
Volatility 1M
53.6%

Performance

1 week
−2.4%
1 month
−8.3%
3 months
−9.8%
6 months
+42.4%
YTD
0.0%
1 year
+5.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has RGEN performed since 11/2016?

$10,000 grew to $50,403 by 20 Nov 2026, which is +17.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is RGEN?

Volatility was 38.9% per year, measured on monthly returns. The largest decline from a peak was −68.3%, with the low in 05/2026.

How does RGEN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, RGEN returned +17.6% at 38.9%. The correlation of monthly returns was 0.35; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Repligen Corp (RGEN): Return and risk | Portfolio Lab